SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

08 Nov 2021 Evaluate
The Sales for the quarter ended September 2021 of Rs. 28831.80 million declined by -36.61% from Rs. 45485.00 millions.The company reported a drastic decline of -75.19% in the quarter ended September 2021 to Rs. 1976.80  millions from Rs. 7969.30 millions  .Operating Profit reported a sharp decline to 4221.00 millions from 12506.90 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 28831.80 45485.00 -36.61 57769.30 79744.90 -27.56 158236.80 133707.70 18.35
Other Income 823.70 431.70 90.80 1263.20 1641.30 -23.04 5898.60 2434.30 142.31
PBIDT 4221.00 12506.90 -66.25 8768.60 23321.50 -62.40 47096.80 29412.90 60.12
Interest 34.40 64.50 -46.67 85.00 168.90 -49.67 286.80 979.10 -70.71
PBDT 4186.60 12442.40 -66.35 8683.60 23152.60 -62.49 46810.00 28433.80 64.63
Depreciation 981.80 1212.50 -19.03 2128.30 2417.10 -11.95 4879.90 4733.30 3.10
PBT 3204.80 11229.90 -71.46 6555.30 20735.50 -68.39 41930.10 23700.50 76.92
TAX 1228.00 3260.60 -62.34 2427.80 5690.90 -57.34 10801.00 4931.70 119.01
Deferred Tax 7.60 51.90 -85.36 -227.00 31.20 -827.56 367.60 8.80 4077.27
PAT 1976.80 7969.30 -75.19 4127.50 15044.60 -72.56 31129.10 18768.80 65.86
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 14.64 27.50 -46.76 15.18 29.25 -48.10 29.76 22.00 35.30

Aurobindo Pharma Share Price

1367.70 -17.95 (-1.30%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×